GVK Biosciences, which provides integrated research services to pharmaceutical and biotechnology companies from its home base in Hyderabad, has opened a new clinical pharmacology unit in Ahmedabad, India.

The new CPU, which will conduct a variety of studies in healthy volunteers, adds 110 beds to the existing capacity of 144 beds at GVK BIO’s clinical pharmacology unit in Hyderabad, which the company says is a leading provider of bioequivalence studies to generic drug companies worldwide. The Hyderabad facility started operations in 2004.

Ahmedabad was the “logical” destination for an extension of GVK BIO’s clinical pharmacology capabilities in India, given the proximity to around 10 contract research organisations and leading pharmaceutical companies, as well as access to some 12,000 healthy volunteers, the company explained.

The new facility is also a gateway to special populations like young or post-menopausal women and patients in areas such as neurology, psychiatry, metabolism and cardiovascular diseases, it noted.

“The opening of the new GVK BIO clinical pharmacology unit reflects our commitment to offer faster recruitment solutions to our customers,” commented Manni Kantipudi, president of GVK Biosciences.

The unit has been audited by the Drug Controller General of India and the company has already started its first study at the new facility, he added.